Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives

Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives

The vasculature is a key player and regulatory component in the multicellular microenvironment of solid tumors and, consequently, a therapeutic target. In colorectal carcinoma (CRC), antiangiogenic treatment was approved almost 20 years ago, but there are still no valid predictors of response. In ad...

Full description

Bibliographic Details
Main Authors:	Anne Jacobsen, Jürgen Siebler, Robert Grützmann, Michael Stürzl, Elisabeth Naschberger
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Cancers
Subjects:	antiangiogenic treatment cancer colorectal cancer endothelial cells tumor microenvironment bevacizumab
Online Access:	https://www.mdpi.com/2072-6694/16/5/890

Similar Items

Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (Avegra®, BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON
by: Alexey A. Tryakin, et al.
Published: (2021-12-01)

STUDY DATA OF KRAS- AND RAS-UNMUTATED (WILD) TYPE OF COLORECTAL CANCER
by: V. A. Gorbunova
Published: (2015-05-01)

Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
by: Sun Weijing
Published: (2012-10-01)

Modern aspects of antiangiogenic therapy in ovarian cancer
by: A. A. Rumyantsev, et al.
Published: (2018-11-01)

Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study
by: Ruth Vera, et al.
Published: (2020-08-01)

The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01)

Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study
by: M. Yu. Fedyanin, et al.
Published: (2021-06-01)

Dysphonia after Bevacizumab Rechallenge: A Case Report
by: Corey A. Carter, et al.
Published: (2015-10-01)

CLINICAL EXPERIENCE OF COMBINED AVASTIN THERAPY IN METASTATIC COLORECTAL CANCER
by: V. A. Ekimov
Published: (2015-02-01)

Anti-angiogenic therapy for ovarian cancer
by: Yolanda García García, et al.
Published: (2020-08-01)

Tolerability profile of bevacizumab in metastatic colorectal cancer: about a Medical Department experience
by: Mohamed Reda Khmamouche, et al.
Published: (2016-10-01)

Retrospective analysis on the clinical efficacy of bevacizumab combined with FOLFOX4 in the first line treatment of metastatic colorectal cancer
by: Eun Mi Lee, et al.
Published: (2017-12-01)

Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
by: Ian Chau, et al.
Published: (2020-03-01)

CLINICAL EXPERIENCE OF PROLONGED BEVACIZUMAB THERAPY IN METASTATIC COLORECTAL CANCER
by: I. S. Bulavina, et al.
Published: (2015-02-01)

Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment – New Findings and Future Perspectives
by: Laurenz Nagl, et al.
Published: (2020-08-01)

The Avastin application in clinical practice in patients with metastatic colorectal cancer: Second interim analysis of the observational AJAX program
by: I V Poddubnaya, et al.
Published: (2014-03-01)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
by: Zhiting Zhao, et al.
Published: (2023-01-01)

Immune Cell Infiltration of the Primary Tumor Microenvironment Predicted the Treatment Outcome of Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients
by: Yixing Wang, et al.
Published: (2021-01-01)

Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study
by: Reem D. Mahmood, et al.
Published: (2021-04-01)

Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
by: Yan Wei, et al.
Published: (2024-03-01)

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
by: Fabi Alessandra, et al.
Published: (2012-10-01)

CD276-Positive Circulating Endothelial Cells Do Not Predict Response to Systemic Therapy in Advanced Colorectal Cancer
by: Elske C. Gootjes, et al.
Published: (2020-01-01)

Targeted Therapy in the Palliative Setting of Colorectal Cancer—Survival and Medical Costs
by: Kamuran Inci, et al.
Published: (2023-06-01)

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
by: M. Toledano-Fonseca, et al.
Published: (2023-03-01)

Metabolic reprogramming of the ovarian cancer microenvironment in the development of antiangiogenic resistance
by: Yue Huiran, et al.
Published: (2023-04-01)

Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment
by: Meng Yuan, et al.
Published: (2022-11-01)

Genetic Variants of <i>ANGPT1</i>, <i>CD39</i>, <i>FGF2</i> and <i>MMP9</i> Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer
by: María Gaibar, et al.
Published: (2021-01-01)

Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis
by: Yu Song, et al.
Published: (2024-02-01)

INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG
by: N. V. Dobrova, et al.
Published: (2015-02-01)

Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications
by: Shinji Rho, et al.
Published: (2023-03-01)

Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
by: Ocvirk Janja, et al.
Published: (2016-06-01)

Extracerebral anaplastic meningioma
by: Guido Carillio, et al.
Published: (2023-08-01)

Mathematical investigation of antiangiogenic monotherapy effect on heterogeneous tumor progression
by: Maxim Borisovich Kuznetsov, et al.
Published: (2017-06-01)

Atypical choroid plexus papilloma treated with single agent bevacizumab
by: Francois G. Kamar, et al.
Published: (2014-03-01)

Bevacizumab treatment of meningeal melanoma metastases
by: Trude G. Simonsen, et al.
Published: (2020-01-01)

Preliminary results of an observational program for estimating the duration of bevacizumab therapy in patients with metastatic colorectal cancer in daily clinical practice
by: I V Poddubnaya, et al.
Published: (2013-03-01)

The Advantage of Bevacizumab in Treating Colorectal Brain Metastasis
by: Hung-Ming Chen, et al.
Published: (2014-09-01)

Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer
by: Kunpeng Fang, et al.
Published: (2024-02-01)

A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer
by: Sheng-Chieh Huang, et al.
Published: (2022-03-01)

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
by: Paola Ulivi, et al.
Published: (2018-01-01)